LifeCell™ Corporation, a KCI company, is on the cutting edge of tissue repair products for use in reconstructive, urogynecologic and orthopedic surgical procedures.
This information is intended only for residents of the United Kingdom. The product information provided in this site is intended only for residents of the United Kingdom. The products discussed herein may have different product labeling in different countries.
Since 1994, LifeCell™ has been a pioneer in the science of regenerative medicine. Our first commercial product, AlloDerm® Regenerative Tissue Matrix, has been used successfully in more than one million grafts and implants globally to date.1 AlloDerm® Tissue Matrix and our next generation soft-tissue repair product, Strattice™ Reconstructive Tissue Matrix, are being used by an increasing number of surgeons for a range of surgical applications including hernia repair, breast reconstruction postmastectomy, breast plastic surgery (breast augmentation revisions) and other reconstructive applications.2
LifeCell’s tissue matrix products are manufactured with proprietary processes that remove cells which can lead to tissue rejection and matrix failure. The resulting a-cellular tissue matrices are strong, safe and resistant to infection. They support tissue regeneration by allowing rapid revascularisation3, white cell migration3 and cell repopulation3 - ultimately transforming into host tissue supporting strong, natural repair.
LifeCell’s innovative technologies have been developed through extensive research and testing. Our products help surgeons to restore many types of tissue damaged through injury, surgery or disease - using the body’s innate regenerative power.
After more than fifteen years of successful use LifeCell’s patented tissue matrix technology remains “first in class” - making LifeCell™ the leader in tissue regeneration.
The information on this website is intended for health care professionals only.
Before use surgeons should review all risk information which can be found in the Instructions for Use (PDF, 4 MB) attached to the packaging of each Strattice™ Reconstructive Tissue Matrix.
1.Data based mainly on U.S. experience.
2.Currently marketed in the United Kingdom is Strattice™ Reconstructive Tissue Matrix for hernia repair and breast reconstruction postmastectomy.
3.Connor J, et al. Retention of structural and biochemical integrity in a biologic mesh supports tissue remodeling in a primate abdominal wall model. Regen Med. 2009;4(2):185-195.
This Web page contains information about products which may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use.